| 000 | 04927naa a22006257i 4500 | ||
|---|---|---|---|
| 001 | UMUN-OA-20261005-PH-058 | ||
| 003 | local | ||
| 005 | 20261005174916.0 | ||
| 006 | m o d | ||
| 007 | cr|||||||||||| | ||
| 008 | 261005s2022 xx o u000 0 eng d | ||
| 024 | 7 |
_a10.1016/j.eclinm.2022.101624 _2doi |
|
| 035 | _a(local)EuropePMC:PMC9417563 | ||
| 040 |
_alocal _beng _clocal |
||
| 041 | 0 | _aeng | |
| 100 | 0 |
_aKin Israel Notarte _eauthor. |
|
| 245 | 1 | 0 |
_aImpact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. / _cKin Israel Notarte; Jesus Alfonso Catahay; Jacqueline Veronica Velasco [and others]. |
| 264 | 1 |
_a[Place of publication not identified] : _bElsevier, _c2022. |
|
| 300 | _a1 online resource (1 article). | ||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 500 | _aThe source lists 13 contributors; the first 12 names are recorded as access points. The complete source author list is retained in the catalogue manifest. | ||
| 500 | _aPublication type: Journal article. | ||
| 500 | _aLinked open-access copy: published version. | ||
| 506 | 0 |
_aOpen access; no subscription required for the linked open-access version. _fUnrestricted online access _2star |
|
| 520 | 3 | _aBackground Although COVID-19 vaccination decreases the risk of severe illness, it is unclear whether vaccine administration may impact the prevalence of long-COVID. The aim of this systematic review is to investigate the association between COVID-19 vaccination and long-COVID symptomatology. Methods MEDLINE, CINAHL, PubMed, EMBASE, and Web of Science databases, as well as medRxiv and bioRxiv preprint servers were searched up to June 20, 2022. Peer-reviewed studies or preprints monitoring multiple symptoms appearing after acute SARS-CoV-2 infection either before or after COVID-19 vaccination collected by personal, telephone or electronic interviews were included. The methodological quality of the studies was assessed using the Newcastle-Ottawa Scale. Findings From 2584 studies identified, 11 peer-reviewed studies and six preprints were included. The methodological quality of 82% ( n =14/17) studies was high. Six studies ( n =17,256,654 individuals) investigated the impact of vaccines before acute SARS-CoV-2 infection (vaccine-infection-long-COVID design). Overall, vaccination was associated with reduced risks or odds of long-COVID, with preliminary evidence suggesting that two doses are more effective than one dose. Eleven studies ( n =36,736 COVID-19 survivors) investigated changes in long-COVID symptoms after vaccination (infection-long-COVID-vaccine design). Seven articles showed an improvement in long-COVID symptoms at least one dose post-vaccination, while four studies reported no change or worsening in long-COVID symptoms after vaccination. Interpretation Low level of evidence (grade III, case-controls, cohort studies) suggests that vaccination before SARS-CoV-2 infection could reduce the risk of subsequent long-COVID. The impact of vaccination in people with existing long-COVID symptoms is still controversial, with some data showing changes in symptoms and others did not. These assumptions are limited to those vaccines used in the studies. Funding The LONG-COVID-EXP-CM study supported by a grant of Comunidad de Madrid. | |
| 540 |
_aCreative Commons Attribution (licence family recorded by the source; version not supplied in metadata). _uhttps://europepmc.org/articles/PMC9417563 |
||
| 546 | _aIn English. | ||
| 588 | 0 | _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source. | |
| 590 | _aCourse allocation: B. Sc. Public Health. | ||
| 650 | 4 | _aVaccine | |
| 650 | 4 | _aSars-cov-2 | |
| 650 | 4 | _aPost-covid Syndrome | |
| 650 | 4 | _aLong-covid Symptoms | |
| 653 | _aB. Sc. Public Health | ||
| 653 | _aUMUN open access collection | ||
| 653 | _avaccination | ||
| 655 | 4 | _aJournal articles. | |
| 700 | 0 |
_aJesus Alfonso Catahay _eauthor. |
|
| 700 | 0 |
_aJacqueline Veronica Velasco _eauthor. |
|
| 700 | 0 |
_aAdriel Pastrana _eauthor. |
|
| 700 | 0 |
_aAbbygail Therese Ver _eauthor. |
|
| 700 | 0 |
_aFlos Carmeli Pangilinan _eauthor. |
|
| 700 | 0 |
_aPrincess Juneire Peligro _eauthor. |
|
| 700 | 0 |
_aMichael Casimiro _eauthor. |
|
| 700 | 0 |
_aJonathan Jaime Guerrero _eauthor. |
|
| 700 | 0 |
_aMa Margarita Leticia Gellaco _eauthor. |
|
| 700 | 0 |
_aGiuseppe Lippi _eauthor. |
|
| 700 | 0 |
_aBrandon Michael Henry _eauthor. |
|
| 773 | 0 |
_tEClinicalMedicine _gVol. 53, (2022), pages/article 101624 _x2589-5370 |
|
| 856 | 4 | 0 |
_uhttps://europepmc.org/articles/PMC9417563 _yRead open-access publication _zOpen access. _70 |
| 884 |
_aCourse selection and automated MARC21 enrichment from Europe PMC metadata. _g20261005 _khttps://europepmc.org/articles/PMC9417563 _qlocal |
||
| 942 | _n0 | ||
| 999 |
_c1330 _d1330 |
||